NI 0801

Drug Profile

NI 0801

Alternative Names: Alpha-IP-10; NI-0801; α-IP-10

Latest Information Update: 02 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NovImmune SA
  • Class Antiallergics; Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL10 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic contact dermatitis; Primary biliary cirrhosis

Most Recent Events

  • 19 Feb 2014 Phase II development in Primary biliary cirrhosis is ongoing in Europe
  • 05 Sep 2011 Phase-II clinical trials in Primary biliary cirrhosis in Italy (Parenteral)
  • 05 Sep 2011 Phase-II clinical trials in Primary biliary cirrhosis in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top